Ipsen and Oncodesign partnered to discover and develop inhibitors for Parkinson's disease and other diseases using Oncodesign's Nanocyclix technology

Oncodesign S.A.

France / Tools, Services, and Manufacturing

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Ipsen Group

France / Mid-Cap Biopharma ($1-$50 billion)

$2,652.0m on 01/06/2012 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced